Dupixent (dupilumab) gets DCGI approval to treat moderate-to-severe atopic dermatitis
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
dupilumab
US FDA accepts Dupixent for priority review in adults with prurigo nodularis
If approved, Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the US
Pfizer’s phase-III Jade trial shows positive results
The trial compares the efficacy of abrocitinib and dupilumab for moderate-to-severe atopic dermatitisa